Loading...
12 Japan Hyperglycemics Reports
Country Covered: Japan
Study Period: 2019 - 2029
Major Players: Novo Nordisk, Eli Lilly, Sanofi, Biocon, Gan & Lee
Country Covered: Japan
Study Period: 2018 - 2029
Major Players: Eli Lilly, Boehringer Ingelheim, Janssen Pharmaceuticals, AstraZeneca, Bristol Myers Squibb
Country Covered: Japan
Study Period: 2019 - 2029
Major Players: Takeda, Bristol-Myers Squibb, Glenmark, Merck and Co., Sanofi Aventis
Country Covered: Japan
Study Period: 2018 - 2029
Major Players: Novo Nordisk, Glenmark, Novartis, Kissei, Biocon
Country Covered: Japan
Study Period: 2019 - 2029
Major Players: Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Biocon Limited, Pfizer Inc.
Country Covered: Japan
Study Period: 2018 - 2029
Major Players: Bristol Myers Squibb, Glenmark Pharmaceuticals, Takeda, Sanofi Aventis, Merck and Co.
Country Covered: Japan
Study Period: 2019- 2029
Major Players: Glenmark Pharmaceuticals, Novartis, Kissei Pharmaceuticals, Biocon, Novo Nordisk A/S
Country Covered: Japan
Study Period: 2019- 2029
Major Players: Sanofi Aventis, Pfizer Inc., Merck & Co., Inc., Torrent Pharma, Dr. Reddy's Laboratories
Country Covered: Japan
Study Period: 2019 - 2029
Major Players: Janssen Pharmaceuticals, Eli Lilly, Bristol Myers Squibb, AstraZeneca Pharmaceuticals, Astellas
Country Covered: Japan
Study Period: 2019 - 2029
Major Players: Novo Nordisk, Sanofi, Eli Lilly, Biocon, Wockhardt
Country Covered: Japan
Study Period: 2019 - 2029
Major Players: Abbott, Sanofi , Mylan Inc, Lupin, Aurobindo Pharma
Country Covered: Japan
Study Period: 2018 - 2029
Major Players: Sanofi Aventis, Novo Nordisk AS, Biocon, Eli Lilly and Company, Julphar